Skip to main content
SpringerLink
Log in

Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids

  • Original Article
  • Flavonoids, Doxorubicin-iron Complex, ICRF-187
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Cancer therapy with the anthracycline doxorubicin (Dox) is limited by cardiomyopathy, which develops in animals and patients after cumulative dosing. Generation of free radicals by Dox may be involved in this cardiotoxicity. Dox binds strongly to metal ions, especially iron(III). This Dox-metal complex stimulates the generation of free radicals through self-reduction of the complex. We investigated the possibility of inhibiting Dox-induced cardiotoxicity by scavenging of free radicals and/or chelating metal ions. The effects of Dox, both alone and in combination with iron-chelating agents, were studied on inotropy of the isolated mouse left atrium, lipid peroxidation (LPO) in cardiac microsomal membranes, ferricytochrome c (cyt.c3+) reduction, and oxygen consumption. The flavonoids 7-monohydroxyethylrutoside (mono-HER) and 7,3′,4′-trihydroxyethylrutoside (tri-HER) and the ethylenediaminetetraacetic acid (EDTA) analogue ICRF-198 and its precursor ICRF-187 were used as iron-chelating agents. The latter were used for comparison since ICRF-187 has been reported to inhibit the cardiotoxic effects of Dox both in vitro and in vivo. Only the flavonoids could inhibit the negative inotropic effect of Dox (35μM) on the mouse left atrium; in the presence of tri-HER (500 μM) the beating force decreased by 18% instead of 50%, whereas mono-HER completely prevented the Dox-induced negative inotropic effect. ICRF-198 and both flavonoids (500 μM) completely inhibited Dox (35μM)-induced LPO, whereas ICRF-187 provided 65% inhibition. The observation that both cyt.c3+ reduction and oxygen consumption induced by the Dox-iron(III) complex (50/16.6 μM Dox3Fr3+) could be inhibited by superoxide dismutase proved the involvement of superoxide anions (O ⊙−2 ). The iron-chelating agents (50 μM) inhibited cyt.c3+ reduction by 91% (mono-HER), 43% (tri-HER), and 100% (ICRF-198). Only mono-HER and ICRF-198 (50 μM) were capable of inhibiting the oxygen consumption by 70% and 43%, respectively. It is concluded that flavonoids offer a good perspective for further studies on the prevention of Dox-induced cardiomyopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bachur NR, Gordan SL, Gee MV (1977) Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 13: 901

    Google Scholar 

  2. Bast A, Haenen GRMM (1990) Antioxidant capacity of constituents of Venoruton. Int J Microcirc Clin Exp 9: 177

    Google Scholar 

  3. Beraldo H, Garnier-Suillerot A, Tosi L, Lavelle F (1985) Iron(III)-Adriamycin and iron(III)-daunorubicin complexes: physicochemical characteristics, interaction with DNA and antitumor activity. Biochemistry 24: 284

    Google Scholar 

  4. Chappell JB (1964) The oxidation of citrate, isocitrate and cis-aconitate by isolated mitochondria. Biochem J 90: 225

    Google Scholar 

  5. De Jong J, Schoofs PR, Onderwater RCA, Van der Vijgh WJF, Pinedo HM, Bast A (1990) Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of the β-adrenoceptor system and reactive oxygen species. Res Commun Chem Pathol Pharmacol 68: 275

    Google Scholar 

  6. De Jong J, Schoofs PR, Snabilié AM, Bast A, Van der Vijgh WJF (1993) The role of biotransformation in anthracyline-induced cardiotoxicity in mice. J Pharmacol Exp Ther 266: 312

    Google Scholar 

  7. Demant EJF (1984) Transfer of ferritin-bound iron to adriamycin. FEBS Lett 176: 97

    Google Scholar 

  8. Dodd NJF, Mukherjee T (1984) Free radical formation from anthracycline antitumour agents and model systems. I. Model naphtoquinones and anthraquinones. Biochem Pharmacol 33: 379

    Google Scholar 

  9. Doroshow JH (1983) Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43: 460

    Google Scholar 

  10. Doroshow JH, Locker GY, Myers CE (1979) Experimental animal models of Adriamycin cardiotoxicity. Cancer Treat Rep 63: 855

    Google Scholar 

  11. Gianni L, Zweier JL, Levy A, Myers CE (1985) Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen. J Biol Chem 260: 6820

    Google Scholar 

  12. Gianni L, Vigano L, Lanza C, Niggeler M, Malatesta V (1988) Role of daunosamine and hydroxyl side chain in reaction with iron and lipid peroxidation by anthracyclines. J Natl Cancer Inst 80: 1104

    Google Scholar 

  13. Green MD, Alderton P, Gross J, Muggia FM, Speyer JL (1990) Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187. Pharmacol Ther 48: 61

    Google Scholar 

  14. Gutteridge JMC (1984) Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron(III) complex. Biochem Pharmacol 33: 1725

    Google Scholar 

  15. Haenen GRMM, Bast A (1983) Protection against microsomal lipid peroxidation by a glutathione dependent heat labile factor. FEBS Lett 159: 24

    Google Scholar 

  16. Hasinoff BB (1989) The interaction of the cardioprotective agent ICRF-187 [(+)-1,2,-bis(3,5-dioxopiperazin-1-yl) propane]; its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 26: 378

    Google Scholar 

  17. Hasinoff BB (1989) Self-reduction of the iron(III)-doxorubicin complex. Free Radical Biol Med 7: 583

    Google Scholar 

  18. Hasinoff BB (1990) The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187. Agents Actions 29: 374

    Google Scholar 

  19. Hasinoff BB, Davey JP, O'Brien PJ (1989) The Adriamycin (doxorubicin) induced inactivation of cytochrome c oxidase depends on the presence of iron or copper. Xenobiotica 19: 231

    Google Scholar 

  20. Havsteen B (1983) Flavonoids, a class of natural products of high pahrmacological potency. Biochem Pharmacol 32: 1141

    Google Scholar 

  21. Herman EH, Ferrans VJ, Young RSK, Hamlin RL (1988) Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res 48: 6918

    Google Scholar 

  22. Hermansen K, Rasmussen IMN, Schou HS (1990) The isolated mouse atria as a new model for testing cardioactive drugs with special reference to doxorubicin (Adriamycin). Pharmacol Toxicol 66: 299

    Google Scholar 

  23. Huang Z-X, May PM, Quinlan KM, Williams DR, Creighton AM (1982) Metal binding by pharmaceuticals. 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 12: 536

    Google Scholar 

  24. Minotti G (1990) NADPH- and Adriamycin-dependent microsomal release of iron and lipid peroxidation. Arch Biochem Biophys 277: 268

    Google Scholar 

  25. Myers CE, Gianni L, Simone SB, Klecker R, Greene R (1982) Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry 21: 1707

    Google Scholar 

  26. Powis G (1987) Metabolism and reactions of quinoid anti-cancer agents. Pharmacol Ther 35: 57

    Google Scholar 

  27. Ryan TP, Samokyszyn VM, Dellis S, Aust SD (1990) Effects of (+)-1,2-bis(3,5-dioxopiperazin-1-yl) propane (ADR-529) on iron catalyzed lipid peroxidation. Chem Res Toxicol 3: 384

    Google Scholar 

  28. Sobol MM, Amiet RG, Green MD (1992) In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane] onto an existing ferric-anthracycline complex. Mol Pharmacol 41: 8

    Google Scholar 

  29. Someya A and Tanaka N (1979) DNA strand scission induced by adriamycin and a clacinomycin A. Antibiotics 32: 839

    Google Scholar 

  30. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Jacquotte-Zeleniuch A, Wernz J, Feit F, Slater W, Blum R, Muggia F (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319: 745

    Google Scholar 

  31. Thompson M, Williams CR (1976) Stability of flavonoid complexes of copper(II) and flavonoid antioxidant activity. Anal Chem Acta 85: 375

    Google Scholar 

  32. Van Acker SABE, Voest EE, Beems DB, Madhuizen HT, De Jong J, Bast A, Van der Vijgh WJF (1993) Cardioprotective properties ofO-(β-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice. Cancer Res 53: 4603

    Google Scholar 

  33. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710

    Google Scholar 

  34. Wallace KB (1986) Nonenzymatic oxygen activation and stimulation of lipid peroxidation by doxorubicin-copper. Toxicol Appl Pharmacol 86: 69

    Google Scholar 

  35. Winterbourn CC (1981) Cytochrome c reduction by semiquinone radicals can be directly inhibited by superoxide dismutase. Arch Biochem Biophys 290: 159

    Google Scholar 

  36. Winterbourn CC (1982) Superoxide-dismutase-inhibitable reduction of cytochrome c by the alloxan radical. Implications for alloxan cytotoxicity. Biochem J 207: 609

    Google Scholar 

  37. Zweier JL (1984) Reduction of O2 by iron-Adriamycin. J Biol Chem 159: 6056

    Google Scholar 

  38. Zweier JL (1985) Iron-mediated formation of an oxidized adriamycin free radical. Biochim Biophys Acta 839: 209

    Google Scholar 

  39. Zweier JL, Gianni L, Muindi J, Myers CE (1986) Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxylgroup. Biochim Biophys Acta 884: 326

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leiden/Amsterdam Center for Drug Research, Division of Molecular Pharmacology, Faculty of Chemistry, Vrije Universiteit, De Boelelaan 1083, 1081 HV, Amsterdam, The Netherlands

    Birgitta C. P. Hüsken, Jan de Jong, Bob Beekman, Robertus C. A. Onderwater & Aalt Bast

  2. Department of Oncology, Free Unversity Hospital, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands

    Wim J. F. van der Vijgh

Authors
  1. Birgitta C. P. Hüsken
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bob Beekman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robertus C. A. Onderwater
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wim J. F. van der Vijgh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aalt Bast
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hüsken, B.C.P., de Jong, J., Beekman, B. et al. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids. Cancer Chemother. Pharmacol. 37, 55–62 (1995). https://doi.org/10.1007/BF00685629

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685629

Key words

Search

Navigation